DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022



Monthly information regarding the total number of voting rights and

total number of shares of the Company as of June 30, 2022 

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

 

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345





Date



Total number of shares Total number of voting rights
06/30/202294,022,679



Total gross of voting rights: 94,022,679







Total net* of voting rights: 92,916,392



* Total net = total number of voting rights attached to shares – shares without voting rights

 

 

 

 

Attachment



EN
20/07/2022

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025 Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presen...

June 12, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participera au prochain congrès EAACI 2025

DBV Technologies participera au prochain congrès EAACI 2025 Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une société biopharmaceutique en phase clinique, annonce aujourd'hui sa participation au congrès European Academy of Allergy and Clinical Immunology (EAACI) qui se tiendra du 13 au 16 juin 2025 à Glasgow, au Royaume-Uni. DBV présentera deux posters, organisera un symposium et tiendra un stand dans le hall d'exposition d...

June 12, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces the Voting Results of its 2025 Combined Gen...

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by t...

June 11, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce les résultats de son Assemblée Générale Mixte...

DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Châtillon, France, le 11 juin 2025 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en phase clinique, a tenu son Assemblée Générale Mixte (l’« Assemblée Générale »). L’Assemblée Générale s’est déroulée au siège social de la Société, sous la présidence de Michel de Rosen, Président du C...

June 11, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information Regarding the Total Number of Voting Rights and Total Numb...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025                                                         Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights05/30/2025136,973,697Total gross of voting rights: 136,973,697Total net* of voting rights: 136,738,528 * Net to...

June 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch